336 related articles for article (PubMed ID: 20848510)
1. Therapy with anti-TNFα antibody enhances number and function of Foxp3(+) regulatory T cells in inflammatory bowel diseases.
Boschetti G; Nancey S; Sardi F; Roblin X; Flourié B; Kaiserlian D
Inflamm Bowel Dis; 2011 Jan; 17(1):160-70. PubMed ID: 20848510
[TBL] [Abstract][Full Text] [Related]
2. Restoration of Foxp3+ Regulatory T-cell Subsets and Foxp3- Type 1 Regulatory-like T Cells in Inflammatory Bowel Diseases During Anti-tumor Necrosis Factor Therapy.
Li Z; Vermeire S; Bullens D; Ferrante M; Van Steen K; Noman M; Rutgeerts P; Ceuppens JL; Van Assche G
Inflamm Bowel Dis; 2015 Oct; 21(10):2418-28. PubMed ID: 26308438
[TBL] [Abstract][Full Text] [Related]
3. Heightened Expression of CD39 by Regulatory T Lymphocytes Is Associated with Therapeutic Remission in Inflammatory Bowel Disease.
Gibson DJ; Elliott L; McDermott E; Tosetto M; Keegan D; Byrne K; Martin ST; Rispens T; Cullen G; Mulcahy HE; Cheifetz AS; Moss AC; Robson SC; Doherty GA; Ryan EJ
Inflamm Bowel Dis; 2015 Dec; 21(12):2806-14. PubMed ID: 26332314
[TBL] [Abstract][Full Text] [Related]
4. Apoptosis of regulatory T lymphocytes is increased in chronic inflammatory bowel disease and reversed by anti-TNFα treatment.
Veltkamp C; Anstaett M; Wahl K; Möller S; Gangl S; Bachmann O; Hardtke-Wolenski M; Länger F; Stremmel W; Manns MP; Schulze-Osthoff K; Bantel H
Gut; 2011 Oct; 60(10):1345-53. PubMed ID: 21459928
[TBL] [Abstract][Full Text] [Related]
5. Increased prevalence of circulating novel IL-17 secreting Foxp3 expressing CD4+ T cells and defective suppressive function of circulating Foxp3+ regulatory cells support plasticity between Th17 and regulatory T cells in inflammatory bowel disease patients.
Ueno A; Jijon H; Chan R; Ford K; Hirota C; Kaplan GG; Beck PL; Iacucci M; Fort Gasia M; Barkema HW; Panaccione R; Ghosh S
Inflamm Bowel Dis; 2013 Nov; 19(12):2522-34. PubMed ID: 24097227
[TBL] [Abstract][Full Text] [Related]
6. Suppressive and Gut-Reparative Functions of Human Type 1 T Regulatory Cells.
Cook L; Stahl M; Han X; Nazli A; MacDonald KN; Wong MQ; Tsai K; Dizzell S; Jacobson K; Bressler B; Kaushic C; Vallance BA; Steiner TS; Levings MK
Gastroenterology; 2019 Dec; 157(6):1584-1598. PubMed ID: 31513797
[TBL] [Abstract][Full Text] [Related]
7. Reciprocal changes of Foxp3 expression in blood and intestinal mucosa in IBD patients responding to infliximab.
Li Z; Arijs I; De Hertogh G; Vermeire S; Noman M; Bullens D; Coorevits L; Sagaert X; Schuit F; Rutgeerts P; Ceuppens JL; Van Assche G
Inflamm Bowel Dis; 2010 Aug; 16(8):1299-310. PubMed ID: 20196149
[TBL] [Abstract][Full Text] [Related]
8. CD4+CD25+CD127low FoxP3+ regulatory T cells in Crohn's disease.
Khalili A; Ebrahimpour S; Maleki I; Abediankenari S; Afrouzi MM
Rom J Intern Med; 2018 Sep; 56(3):158-166. PubMed ID: 29453928
[TBL] [Abstract][Full Text] [Related]
9. Anti tumour necrosis-alpha therapy increases the number of FOXP3 regulatory T cells in children affected by Crohn's disease.
Ricciardelli I; Lindley KJ; Londei M; Quaratino S
Immunology; 2008 Oct; 125(2):178-83. PubMed ID: 18422560
[TBL] [Abstract][Full Text] [Related]
10. Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor alpha therapies.
Magro F; Portela F
BioDrugs; 2010 Dec; 24 Suppl 1():3-14. PubMed ID: 21175228
[TBL] [Abstract][Full Text] [Related]
11. Lack of correlation between Treg quantification assays in inflammatory bowel disease patients.
Brandhorst G; Petrova DT; Weigand S; Eberle C; von Ahsen N; Schmitz J; Schultze FC; Raddatz D; Karaus M; Oellerich M; Walson PD
World J Gastroenterol; 2015 Mar; 21(11):3325-9. PubMed ID: 25805940
[TBL] [Abstract][Full Text] [Related]
12. Discrete changes in circulating regulatory T cells during infliximab treatment of Crohn's disease.
Hvas CL; Kelsen J; Agnholt J; Dige A; Christensen LA; Dahlerup JF
Autoimmunity; 2010 Jun; 43(4):325-33. PubMed ID: 20298123
[TBL] [Abstract][Full Text] [Related]
13. Decrease of CD4(+) CD25(+) CD127(low) FoxP3(+) regulatory T cells with impaired suppressive function in untreated ulcerative colitis patients.
Mohammadnia-Afrouzi M; Zavaran Hosseini A; Khalili A; Abediankenari S; Hosseini V; Maleki I
Autoimmunity; 2015; 48(8):556-61. PubMed ID: 26333292
[TBL] [Abstract][Full Text] [Related]
14. FOXP3⁺ T regulatory cell modifications in inflammatory bowel disease patients treated with anti-TNFα agents.
Guidi L; Felice C; Procoli A; Bonanno G; Martinelli E; Marzo M; Mocci G; Pugliese D; Andrisani G; Danese S; De Vitis I; Papa A; Armuzzi A; Rutella S
Biomed Res Int; 2013; 2013():286368. PubMed ID: 24063002
[TBL] [Abstract][Full Text] [Related]
15. FOXP3+ regulatory T-cell counts correlate with histological response in Crohn's colitis treated with infliximab.
Sloan S; Maxwell P; Salto-Tellez M; Loughrey MB
Pathol Int; 2014 Dec; 64(12):624-7. PubMed ID: 25354875
[TBL] [Abstract][Full Text] [Related]
16. Anti-TNF-alpha loss of response is associated with a decreased percentage of FoxP3+ T cells and a variant NOD2 genotype in patients with Crohn's disease.
Juanola O; Moratalla A; Gutiérrez A; Sempere L; Zapater P; Giménez P; Almenta I; Peiró G; González-Navajas JM; Such JF; Francés R
J Gastroenterol; 2015 Jul; 50(7):758-68. PubMed ID: 25500977
[TBL] [Abstract][Full Text] [Related]
17. Adalimumab treatment in Crohn's disease does not induce early changes in regulatory T cells.
Dige A; Hvas CL; Deleuran B; Kelsen J; Bendix-Struve M; Dahlerup JF; Agnholt J
Scand J Gastroenterol; 2011 Oct; 46(10):1206-14. PubMed ID: 21793633
[TBL] [Abstract][Full Text] [Related]
18. Accuracy of Rapid Fecal Calprotectin Test in Monitoring Inflammatory Bowel Diseases Under Treatment with TNFα Antagonists.
Tursi A; Elisei W; Picchio M; Giorgetti G; Brandimarte G
Dig Dis Sci; 2015 May; 60(5):1406-13. PubMed ID: 25445163
[TBL] [Abstract][Full Text] [Related]
19. Long-term outcome of tumor necrosis factor alpha antagonist's treatment in pediatric Crohn's disease.
Assa A; Hartman C; Weiss B; Broide E; Rosenbach Y; Zevit N; Bujanover Y; Shamir R
J Crohns Colitis; 2013 Jun; 7(5):369-76. PubMed ID: 22483567
[TBL] [Abstract][Full Text] [Related]
20. Balance of Treg versus T-effector cells during systemic treatment with adalimumab and topical treatment with calcipotriol-betamethasone dipropionate ointment.
Keijsers RR; Joosten I; Hendriks AG; Koenen HJ; van Erp PE; van de Kerkhof PC
Exp Dermatol; 2015 Jan; 24(1):65-7. PubMed ID: 25355140
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
